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Summary 
Human pluripotent stem cells (hPSCs) and mesenchymal stromal/stem cells (hMSCs) are clinically-
relevant sources for cellular therapies and for modeling human development and disease. Many 
stem cell-based applications rely on the ability to activate several endogenous genes 
simultaneously to modify cell fate. However, genetic intervention of these cells remains challenging. 
Several catalytically-dead Cas9 (dCas9) proteins fused to distinct activation domains can modulate 
gene expression when directed to their regulatory regions by a specific single guide RNA (sgRNA). 
Here, we have compared the ability of the first-generation dCas9-VP64 activator and the second-
generation systems, dCas9-SAM and dCas9-SunTag, to induce gene expression in hPSCs and 
hMSCs. Several stem cell lines were lentivirally-transduced with each activator, selected using 
antibiotic resistance or flow cytometry, and tested for single and multiplexed gene activation. When 
the activation of several genes was compared, all three systems induced specific and potent gene 
expression in both single and multiplexed settings, but the dCas9-SAM and dCas9-SunTag 
systems resulted in the highest and most consistent level of gene expression. Simultaneous 
targeting of the same gene with multiple sgRNAs did not result in additive levels of gene expression 
in hPSCs nor hMSCs. We demonstrate the robustness and specificity of second-generation dCas9 
activators as tools to simultaneously activate several endogenous genes in clinically-relevant 
human stem cells. 
Significance Statement 
Different dCas9-based transcriptional activators induce potent and reliable gene activation, both in 
single and multiplexed approaches, in clinically-relevant stem cells (hPSCs and hMSCs). The 
second generation systems, dCas9-SAM and dCas9-SunTag, resulted in the highest level of gene 
expression, and simultaneous targeting of the same gene with multiple sgRNAs did not result in 
additive levels of gene expression. Dead-Cas9 activators represent robust and specific genome-
editing tools to activate endogenous gene expression in clinically-relevant human stem cells. 
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Introduction 
Human pluripotent stem cells (hPSC) including both human embryonic stem cells (hESC) and 
human induced pluripotent stem cells (hiPSC) have the unique ability to self-renew indefinitely and 
to differentiate, potentially, into all cell types of the human body [1, 2]. They provide an 
unprecedented system to interrogate early human development and to provide a potential clinically-
relevant cell source for regenerative medicine [3, 4]. Moreover, hiPSCs offer a unique platform for 
the in vitro generation of patient-specific differentiated cells for personalized therapies, disease 
modelling and drug screening [3, 4]. Similarly, mesenchymal stem cells (MSCs) are self-renewing 
multipotent cells present in a wide range of tissues that are capable of differentiating into various 
tissues of mesodermal origin and display unique immunosuppressive properties [5]. MSCs 
represent one of the most promising adult stem cells being used worldwide in a wide array of clinical 
applications involving autoimmunity, hemato-oncology, traumatology and cardiology [6-8].  
 
The success of human stem cell-based applications often rely on methods to precisely edit the 
donor/patient-specific genome and/or to regulate gene expression. Manipulation of gene 
expression has generally involved the delivery of exogenous cDNA using expression or viral 
vectors. However in recent years, we have witnessed the development of strategies to activate the 
expression of endogenous gene expression using an adapted version of the clustered regularly 
interspaced short palindromic repeat (CRISPR)/Cas9 system. This system was originally 
developed as a powerful and versatile tool for genome editing relying on the endonuclease (Cas9) 
being directed to a specific genomic site by a short guide RNA (sgRNA), resulting in a precise break 
in the target DNA [9, 10]. Mutations in residues involved in DNA catalysis have generated Cas9 
proteins that lack nuclease activity while preserving DNA binding [11, 12]. When fused to 
effector/activation domains such as VP64, VPR or p65 and directed to regulatory region of a 
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genomic locus using sgRNAs, these nuclease-null, catalytically-dead Cas9 (dCas9) variants have 
been shown to modulate endogenous gene expression [11, 13-15]. Recently, Chavez et al. 
compared the first-generation dCas9-VP64 activator with various second-generation dCas9 
activators including dCas9-VPR, dCas9-SAM, and dCas9-SunTag, in several human, mouse and 
fly cell lines and demonstrated the robustness and versatility of each system [16]. Here, we set out 
to compare single and multiplexed gene activation of several endogenous genes in clinically-
relevant hPSCs and hMSCs using first-generation dCas9-VP64 activator and the second-
generation activators dCas9-SAM and dCas9-SunTag. Our data demonstrate that all dCas9 
systems can induce specific and potent gene expression but the second generation systems result 
in the highest and most consistent level of gene expression in these cell types. We provide 
guidance for laboratories wishing to adopt dCas9 activator technology to modulate gene expression 
in human stem cells. 
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Results 
dCas9-VP64 is a fusion between the dCas9 protein and a VP64 transactivating domain [17]. 
dCas9-SAM represents a modified dCas9-VP64 system using a sgRNA that incorporates two 
protein-binding aptamers (MS2) capable of recruiting the transcriptional activators p65 and HSF1 
(MCP-p65-HSF1) to the targeted promoter [18]. The dCas9-SunTag system is a fusion between 
the dCas9 protein to a tail of GCN4 peptides that can recruit up to ten copies of scFV-VP64, that 
amplifies the activation signal [19] (Figure 1A). We set out to compare these three dCas9 activators 
in clinically-relevant hPSCs and hMSCs. Two different hPSC lines were used: the hESC line H9 
and a hiPSC line previously generated and characterized in our laboratory [20]. Two distinct hMSC 
lines were used, one derived from bone marrow (BM) and another from adipose tissue (Ad). Human 
PSCs and MSCs were lentivirally infected with each dCas9 system at identical multiplicity of 
infection (MOI) of 6 to normalize for integration events, and transduced cells were subsequently 
selected using antibiotic resistance or flow cytometry (Figure 1B). Stable expression of either 
dCas9 activator system did not alter the homeostasis and potency of either hPSCs or hMSCs 
(Figure 1 and 2). Antibiotic/FACS-selected modified hPSC and hMSCs were maintained for >20 
and >10 passages, respectively, and retained normal morphology (Figure 1C and 2A). Each 
transgenic stem cell line expressed comparable levels of Cas9, and also showed appropriate 
expression of the corresponding activator components (VP64, MCP and scFV) (Figure 1D and 
2B). All transgenic hPSCs retained the expression of pluripotency-associated transcription factors 
(Figure 1E), the surface marker, SSEA4 (Figure 1F), and the formation of teratomas in NSG mice 
which comprised tissues representing all three germ layers (Figure 1G) Similarly, transgenic 
hMSCs retained typical MSC immunophenotype (CD45-CD73+CD90+CD105+, Figure 2C) and 
differentiated equally well towards adipogenic and osteogenic lineages (Figure 2D). 
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The performance of dCas-VP64, dCas-SAM and dCas9-SunTag was compared across several 
endogenous genes representative of ectoderm (NEUROD1), endoderm (FOXA2) and mesoderm 
(CXCR4) germ layers. Three different sgRNAs were designed in the proximal promoter (up to 250 
base pairs (bp) upstream of the transcription start site) for each target gene, cloned in a lentiviral 
vector containing a Puromycin-resistance cassette and transduced into the transgenic hPSC/hMSC 
lines. Gene expression was then analysed in puromycin-selected cells (Figure 3A). All three dCas9 
activator systems demonstrated the ability to induce robust gene expression regardless of the locus 
targeted, with the second-generation systems, dCas9-SAM and/or dCas9-SunTag, resulting in 
higher levels of gene expression more consistently in both hPSCs (Figure 3B) and hMSCs (Figure 
3C). Overall, the dCas9-SAM and dCas9-SunTag systems activated gene expression to 
comparable levels in hPSCs but the dCas9-SunTag tended to activate gene expression to a slightly 
higher level than dCas9-SAM in hMSCs. These data indicate that intrinsic differences in the cellular 
and (epi)genetic nature of hPSCs and hMSCs may impact on the performance of dCas9 activator 
systems. There was a slight (p>0.05) variation in gene activation between the different sgRNAs 
that were used to target the same locus but no correlation was observed between the promoter 
distal-proximal region targeted by each sgRNA and the levels of gene expression (Figure 3B and 
C). Consistent with previous reports, we noticed a negative correlation between the basal gene 
expression state and the magnitude of activation of a given gene [16, 18, 21, 22]. To analyse the 
effect of recruiting multiple dCas9 activators complexes to the same locus, we transduced the cells 
with a mixture of the three different sgRNAs directed against distinct promoter regions. 
Simultaneous targeting of the same gene with multiple sgRNAs did not lead to additive levels of 
gene expression in either hPSCs or hMSCs, suggesting that the most efficient individual sgRNA 
marks a gene activation plateau for each dCas9 activator (Figure 3B and C).  
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Human stem cell-based applications rely on the ability to simultaneously activate several 
endogenous genes with the potential to modify cell fate. Dead Cas9-based transcriptional activators 
are especially suitable to target multiple loci, requiring only the provision of one sgRNA for each 
gene to be targeted. We next analysed the feasibility to multiplex gene activation in both hPSCs 
and hMSCs. The three dCas9 activator systems performed well upon multiplexing gene activation, 
although the second-generation dCas9-SAM and dCas9-SunTag systems appeared superior to 
the dCa9-VP64 system at least in two out of the three genes targeted (Figure 4A and B). We next 
analyzed the top in silico-predicted off-targets of FOXA2 sgRNA (MEXA3, FUT11 and BTBD17), 
NEUROD1 sgRNA (CCDC88C, CLSTN1 and DUSP27) and CXCR4 sgRNA (TUSC5, CHRFAM7A 
and ADRA2B) and found them all consistently unaltered, demonstrating the high specificity of all 
dCas9 activators in both hPSCs (Figure 4C) and hMSCs (Figure 4D). Taken together, our study 
demonstrate the robustness and specificity of dCas9 activators as a mean to simultaneously 
activate multiple transcription factors in human clinically-relevant stem cells. 
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Discussion 
Human PSCs and MSCs are relevant cell sources which hold great promise in both basic and 
clinical research [4]. These applications largely rely on robust methods to precisely control gene 
expression and to simultaneously activate multiple endogenous genes with the potential to modify 
cell fate and/or cell function. Unfortunately, long-term in vitro maintenance of stemness and precise 
genetic manipulation using exogenous overexpression systems have long remained daunting 
tasks. Recently, the CRISPR/Cas9 system has arisen as a unique, powerful and versatile tool for 
genome editing in a wide range of cell types including stem cells. More recently, dCas9 variants 
lacking nuclease activity while preserving DNA binding have been reported [11, 12]. When fused 
to activation domains such as VP64, VPR, or p65 they can precisely modulate endogenous gene 
expression in any given locus within the genome when directed to their regulatory regions by a 
specific sgRNA, thus representing a versatile tool to regulate locus-specific gene expression [11, 
13-15].  
 
Here, we have compared the first-generation dCas9-VP64 activator with the second-generation 
systems dCas9-SAM and dCas9-SunTag for the first time in clinically relevant human stem cells. 
Importantly, we report for the first time that the stable expression of each of the three dCas9 
activators is compatible with stem cell homeostasis and potency, which is a critical requisite for any 
downstream stem cell application. The three activator systems show the ability to induce potent 
gene expression in both single and multiplexed gene activation settings. Multiplexed gene 
activation in stem cells is highly desired because a simultaneously activation of several master 
transcription factors is key to modulate complex transcriptional networks dictating stem cell fate. 
Despite initial work suggesting a general decrease in gene activation upon multiplexing [18, 23], 
our data confirms the robustness of these systems as tools to actuate complex transcriptional 
multiplexed regulation [16]. In line with previous studies, the second generation systems dCas9-
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SAM and dCas9-SunTag delivered higher and more consistent levels of gene expression than 
dCas9-VP64. Interestingly, the dCas9-SAM and dCas9-SunTag systems performed at a 
comparable level in hPSCs whereas the dCas9-SunTag was slightly superior in hMSCs. This 
indicates that intrinsic cellular and (epi)genetic differences between hPSCs and hMSCs may impact 
the performance of dCas9 activator systems. In fact, differences in chromatin accessibility between 
hESCs and hESC-derived MSCs have been reported [24]. We have also demonstrated that 
simultaneous targeting of the same gene with multiple sgRNAs did not lead to additive levels of 
gene expression in neither human PSCs nor MSCs suggesting that the most efficient individual 
sgRNA marks a gene activation plateau for each dCas9 activator. This is in contrast to that 
described by Chavez et al [16] for other cell lines that did not include stem cells. This could either 
reflect the different nature of the cells targeted or differences in the DNA delivery methods or both. 
It might also be the fact that each system depends upon the recruitment of different downstream 
transcriptional effectors, so the availability of these within the cells may favour certain systems. In 
summary, our work reveals the robustness, specificity and versatility of all dCas9 activators in 
single and multiplexed gene activation systems in clinically-relevant human stem cells and 
demonstrated the superior levels of gene activation by the second-generation systems. 
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Experimental Procedures 
Contact for reagent and resource sharing 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Pablo Menendez (pmenendez@carrerasresearch.org). 
 
hPSC and hMSC culture 
Two hPSC lines were used: the hESC line H9 obtained from Wicell (Madison, WI), and a hiPSC 
line previously generated in our laboratory from B-cell progenitors [20]. Both hPSCs were 
maintained on Matrigel (BD)-coated plates in hESC medium as extensively reported by our group 
[25-27]. hESC media was changed daily and hPSC cultures were split weekly. Bone marrow (BM)- 
and adipose tissue (Ad)-derived human MSC cultures were maintained in Advanced DMEM (Gibco) 
supplemented with 10% fetal bovine serum (Sigma), L-glutamine, and penicillin-streptomycin-
amphotericin B (Gibco), as previously reported by our group [28]. hMSC cultures were assessed 
daily for changes in growth rates and morphology and split every 8-10 days. Approval for 
hESC/hiPSC work was obtained from the Spanish National Embryo Ethical Committee (26/2013).  
 
dCAS9 and sgRNAs lentivectors  
All the vectors used in this study were obtained from Addgene: dCAS9-VP64 (#61425), MCP-p65-
HSF1 (#61426), dCAS9-10xGCN4 (#60903) and scFv-VP64 (#60904). The final constructs used 
to generate hPSC/hMSCs stably expressing the different transcriptional activators are: VP64 
(dCAS9-VP64), SunTag (dCAS9-10xGCN4 + scFv-VP64) and SAM (dCAS9-VP64 + MCP-p65-
HSF1) (Figure 1A). For sgRNA delivery, both the Lentiguide-Puro (#52963) or sgRNA(MS2)-puro 
(#73795) backbone was Golden-Gate cloned with all the guide variants according to the 
established protocol [18]. NEUROD1 and CXCR4 sgRNAs sequences were taken from Chavez et 
al (2016). Best scored FOXA2 sgRNAs sequences were defined with the CRISPRa/i sgRNA 
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designer tool from the BROAD institute. The individual sgRNAs targeting FOXA2 at bp -42, 
NEUROD1 at bp -221 and CXCR4 at bp -162 were used in multiplexing gene activations 
experiments. 
 
Virus production and transduction of hPSC/hMSC 
A second generation lentiviral production system was used to produce viral particles in HEK293T 
cells. The psPAX2 packaging plasmid, pMD2.G envelope and the lentiviral transfer vector were co-
transfected using PEI (Polysciences) as previously detailed [29]. Virus-containing supernatants 
were harvested 48-72h post-transfection, concentrated by ultracentrifugation and titered in 293T 
cells. For transduction, hPSC/hMSC were split 48h before exposure to viral supernatants, MOI of 
6. Infected cells were expanded in the presence of blasticidine (3 µg/ml for VP64) and blasticidine 
plus hygromycin (3 µg/ml and 60 µg/ml for SAM). SunTag-infected cells were FACS-sorted using 
GFP and BFP reporters, thus generating hPSC/hMSCs stably expressing the different 
transcriptional activators (Figure 3B). To select for integration of gRNAs construct, puromycin (0.3 
µg/ml) was added to the cultures 
 
Quantitative RT-PCR 
Total RNA was extracted with Maxwell® RSC simplyRNA cells kit (Promega) and subsequently 
incubated with TurboDNAse (Ambion) to remove potential genomic contamination. Reverse 
transcription was performed with 500ng RNA using Superscript III and random hexamers primers 
(Invitrogen). cDNA was diluted 1:4 and 1 ul was used for each 10ul reaction. Real-time PCR was 
performed with Power up SYBR green master mix (Applied biosystems) in triplicate on a Biorad 
CFX384 real-time system. All primer pairs were designed with Primer-Blast software and validated 
by gel electrophoresis to amplify specific single products. A standard curve with serial dilution of 
cDNA was always performed to guarantee correct amplification of primer pairs. GAPDH was used 
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as a housekeeping gene. Table S1 shows the sequences of all primers and gRNAs used in this 
study. For the off-targets analysis, the top three in silico-predicted (gRNA design checker, IDT) off-
targets for FOXA2 -42 (MEXA3, FUT11 and BTBD17), NEUROD1 -221 (CCDC88C, CLSTN1 and 
DUSP27) and CXCR4 -162 (TUSC5, CHRFAM7A and ADRA2B) have been checked by Real-time 
PCR in all the systems multiplex experiments for both hMSCs and hPSCs. 
 
Flow cytometry analysis 
The following antibodies (Becton Dickinson, San Jose, CA) were used in FACS experiments: 
SSEA-4-V450, CD73-BV510, CD105-FITC, CD90-APC, and CD45 APC-Cy7. For staining, 200000 
cells were resuspended in 200 ul PBS+2% FBS with 1:100 antibody dilution, for 20min at 4ºC. Cells 
were then washed twice with PBS and acquired on a FACS Canto-II flow cytometer equipped with 
FACS Diva analysis software (Becton Dickinson) 
 
Adipogenic and osteogenic in vitro differentiation of hMSC cultures 
Human MSC differentiation was assessed by growing hMSC in specific differentiation media for 2-
3 weeks according to manufacturer's instructions (Lonza, Switzerland). The detailed differentiation 
procedure is described elsewhere [28]. Briefly, for adipogenic differentiation, cells were cultured in 
Adipogenic MSC Differentiation BulletKit (Lonza) and differentiated cells were stained with Oil Red-
O (Sigma). For osteogenic differentiation, cells were cultured in Osteogenic MSC Differentiation 
BulletKit (Lonza) and differentiated cells were stained with Alizarin Red-S (Sigma) [28]. 
 
Teratoma formation assay 
Undifferentiated hESC/hiPSC cultures at 80-90% confluence were collected through enzymatic 
dissociation using collagenase IV, and 2 million cells were re-suspended and injected with 250 µl 
DMEM and 50µl Matrigel subcutaneously in the back of the NSG mice [30]. Tumors generally 
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developed within 6-10 weeks. When tumours reached 1cm diameter, mice were sacrificed and the 
teratomas removed and fixed overnight in paraformaldehyde-containing solution. Teratomas were 
then embedded in paraffin, sectioned and stained for hematoxylin & eosin to assess the presence 
of cells representing the three germ layers [30]. Animal experimentation protocols was approved 
by the Animal Care Committee of the PRBB. 
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Figure Legends 
Figure 1. Transgenic hPSCs expressing dCas9 transcriptional activators remain pluripotent. 
(A) Schematic of the different dCas9 transcriptional activators used in this study, VP64, SAM and 
SunTag. (B) Schematic of the generation of stable transgenic hPSCs-VP64, hPSC-SAM and 
hPSC-SunTag lines. (C) hESC-like morphology of representative colonies from hPSCs-VP64, 
hPSC-SAM and hPSC-SunTag lines. (D) RT-PCR confirming expression of the different dCas9 
system components in the different transgenic hPSC lines. (E) qRT-PCR expression of the 
indicated pluripotency genes in hPSCs-VP64, hPSC-SAM and hPSC-SunTag lines (n=2). (F) 
Representative FACS data confirming expression of the pluripotency surface maker SSEA-4 in 
hPSCs-VP64, hPSC-SAM and hPSC-SunTag lines. Insets represent unstained cells. (G) hPSCs-
VP64, hPSC-SAM and hPSC-SunTag cells similarly formed teratomas in NSG mice. Left panels 
show macroscopic teratomas. Right panels show cellular structures representing the three germ 
layers.  
 
Figure 2. Transgenic hMSC expressing dCas9 transcriptional activators remain multipotent. 
(A) Phase-contrast morphology of hMSC-VP64, hMSC-SAM and hMSC-SunTag cultures revealing 
normal fibroblastoid-like morphology. (B) RT-PCR confirming expression of the different dCas9 
system components in transgenic hMSC cultures. (C) FACS analysis revealing bona fide MSC 
immunophenotype (CD45-CD73+CD90+CD105+) for hMSC-VP64, hMSC-SAM and hMSC-
SunTag cultures. (D) hMSC-VP64, hMSC-SAM and hMSC-SunTag retained osteogenic (bottom 
panels show alizarin red staining) and adipogenic (upper panels show oil red staining) 
differentiation potential.  
 
Figure 3. Direct comparison of the three dCas9 transcriptional activators in both hPSCs and 
hMSCs. (A) Schematic workflow for the dCas9-mediated transcriptional activation. (B, C) Gene 
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expression analysis by qRT-PCR for FOXA2 (endoderm), NEUROD1 (ectoderm) and CXCR4 
(mesoderm) in hPSCs (n=4 independent experiments using 2 hESCs and 2 iPSC lines) (B) and 
hMSCs (n=4 independent experiments with 2 BM-MSC = and 2 Ad-MSC) (C). Three sgRNAs were 
tested for each gene. The genomic localization of each gRNA relative to the TSS is shown. sgRNAs 
were used individually or pooled. Gene expression is represented as fold change relative to non-
transduced (NT) cells. Statistical significance was determined by Student’s t test (two-tail). *p<0.05, 
**p<0.01. 
 
Figure 4. Multiplexed activation of endogenous genes and off-target analyses in both hPSCs 
and hMSCs. Both hPSCs (A) and hMSCs (B) were simultaneously transduced with three sgRNAs, 
one for each gene. Gene expression is shown as fold change relative to NT cells. (C, D) Analysis 
of the top in silico-predicted off-targets of FOXA2 sgRNA (MEXA3, FUT11 and BTBD17), 
NEUROD1 sgRNA (CCDC88C, CLSTN1 and DUSP27) and CXCR4 sgRNA (TUSC5, CHRFAM7A 
and ADRA2B) in hPSCs (B) and hMSCs (C). Statistical significance was determined by Student’s 
t test (two-tail). *p<0.05, **p<0.01. n=4 independent experiments. 
 
 
 
 
 
 
 
 
 
 

ASAM
4X
VP64
4X
WT
4X
SunTag
4X
hMSCs
40X40X40X 40X
4X4X4X 4X
C
102 105
10
2
10
5
102 105
10
2
10
5
102 105
10
2
10
5
102 105
10
2
10
5
CD105
102 105
10
2
10
5
C
D
73
CD90
102 105
10
2
10
5
C
D
45
102 105
10
2
10
5
102 105
10
2
10
5<1% <1% <1%<1%
D
B
dCas9
VP64
MCP
scFV
GAPDH
W
T
V
P
64
S
A
M
S
un
Ta
g
H
2O
RT-PCR
Petazzi et al. Figure 2
WT VP64 SAM SunTag
A
liz
ar
in
 R
ed
O
il 
R
ed
 O
human PSCs/MSCs
Transduction
FOXA2
NEUROD1
CXCR4
NT 
guide RNAs
Puromycin
Selection
5 days
VP64
SAM
SunTag
qRT-PCR
RNA extraction
cDNA synthesis
A
B
Petazzi et al. Figure 3
C
hPSCs
hMSCs
-42 -179 -248 pooled
gRNAs
1
10
100
1000
10000
FOXA2
-33 -164 -221
1
10
100
1000
10000
100000
NEUROD1
-116 -162 -193
1
10
100
1000
CXCR4
R
el
at
iv
e 
m
R
N
A
 e
xp
re
ss
io
n *
*
***
individual gRNAs
pooled
gRNAs
individual gRNAs
pooled
gRNAs
individual gRNAs
* *
1
10
100
1000
10000
100000
FOXA2
1
10
100
1000
10000
NEUROD1
1
10
100
1000
10000
CXCR4
R
el
at
iv
e 
m
R
N
A
 e
xp
re
ss
io
n
* * *
-42 -179 -248 pooled
gRNAs
individual gRNAs
-33 -164 -221 pooled
gRNAs
individual gRNAs
-116 -162 -193 pooled
gRNAs
individual gRNAs
*
* **
p =0,0571
VP64
SAM
SunTag
VP64
SAM
SunTag
*
*
*
APetazzi et al. Figure 4
hPSCs
FOXA2 NEUROD1 CXCR4
1
10
100
1000
10000
100000
1000000
VP64
SAM
SunTag
***
*
FOXA2 NEUROD1 CXCR4
1
10
100
1000
10000
** *
*
hMSCs
B
MEX3A FUT11 BTBD17 CCDC88C CLSTN1 DUSP27 TUSC5 CHRFAM7A ADRA2B
0.1
1
10
100
1000
10000
hPSCs off-Targets
MEX3A FUT11 BTBD17 CCDC88C CLSTN1 DUSP27 TUSC5 CHRFAM7A ADRA2B
0.1
1
10
100
1000
10000
C
hMSCs off-Targets
D
Table S1. List of gRNAs and primers used in this study 
gRNAs Sequence 
FOXA2 -42 ggcgggtgctccctaccgcg 
FOXA2 -179 ccacttccaactaccgcctc 
FOXA2 -248 tgattgctggtcgtttgttg 
NEUROD1 -33 aggtccgcggagtctctaac 
NEUROD1 -164 acctgcccatttgtatgccg 
NEUROD1 -221 aggggagcggttgtcggagg 
CXCR4 -116 gcagacgcgaggaaggagggcgc 
CXCR4 -162 ccgaccacccgcaaacagca 
CXCR4 -193 gcctctgggaggtcctgtccggctc 
NT cggaggctaagcgtcgcaac 
    
Primers Sequence 
Cas9_F agcacgtggcacagatcctgg 
Cas9_R ggaaatccttccggaaatcgg 
VP64_F aaaagaggaaggtggcggcc  
VP64_R cgtcactgccgagcatgtcg  
MS2_F aaggtgacatgcagcgtcagg 
MS2_R ccatgttcaggtaggacctcc 
scFV_F tgatcggcgacaaggccacc 
scFV_R gcgcttcagctccaccttgg 
GAPDH_F gcaccgtcaaggctgagaac 
GAPDH_R agggatctcgctcctggaa 
OCT4_F gggtttttgggattaagttcttca 
OCT4_R gcccccaccctttgtgtt 
CRIPTO_F cggaactgtgagcacgatgt 
CRIPTO_R gggcagccaggtgtcatg 
DNMT3B_F gctcacagggcccgatactt 
DNMT3B_R gcagtcctgcagctcgagttta 
FOXA2_F cacgagccgtccgactggag 
FOXA2_R atggcggccgccgacatgc  
NEUROD1_F ggatgacgatcaaaagcccaa 
NEUROD1_R gcgtcttagaatagcaaggca 
CXCR4_F actacaccgaggaaatgggct 
CXCR4_R cccacaatgccagttaagaaga 
